WO2008004834A1 - Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf - Google Patents
Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf Download PDFInfo
- Publication number
- WO2008004834A1 WO2008004834A1 PCT/KR2007/003294 KR2007003294W WO2008004834A1 WO 2008004834 A1 WO2008004834 A1 WO 2008004834A1 KR 2007003294 W KR2007003294 W KR 2007003294W WO 2008004834 A1 WO2008004834 A1 WO 2008004834A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- antibody
- egf receptor
- cancer
- seq
- light chain
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2863—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for growth factors, growth regulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
- C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/52—Constant or Fc region; Isotype
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/55—Fab or Fab'
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2319/00—Fusion polypeptide
Definitions
- the present invention relates to a humanized antibody having high binding specificity to EGF receptor and excellent stability, more precisely a humanized monoclonal antibody composed of complementarity determining region derived from an immunized rabbit and framework region induced from a human immunoglobulin and an anticancer composition containing the same.
- Epidermal growth factor is a polypeptide hormone stimulating mitosis of epidermal cells and epithelial cells. EGF acts by binding with high affinity to epidermal growth factor receptor (EGFR) on the cell surface and stimulating the intrinsic protein-tyrosine kinase activity of the receptor.
- EGFR epidermal growth factor receptor
- EGF receptor is a transmembrane protein of approximately 170 kDa and is a genetic product of c-erb-B, a proto-oncogen.
- EGF receptor is a tumor- related cell surface membrane protein, so that it has been widely used as a target of the development of a mouse monoclonal antibody (430) highly binding specifically to
- EGF receptor using an osteosarcoma cell line 791T as an antigen (Durrant, et al., Prenatal Diagnosis, 14, 131-140,
- the phage-antibody library provides an alternative technique substituting hybridoma technique in order to separate an antibody from an immunized animal.
- the hybridoma technique is based on the immortalization of cells generating an antibody.
- the phage-antibody library technique is based on the immortalization of a gene encoding a target antibody (Winter, G. and Milstein, C, Nature, 349, 293-299, 1991).
- This phage-antibody technique is summarized as follows; heavy chain- variable region and light chain variable region genes are amplified by PCR, the variable region (V) is forced to bind to be expressed as an antibody fragment on the surface of the phage particle, and then the phage- antibody binding to the corresponding antigen is screened by the phage-antibody library.
- the hybridoma technique is especially useful to separate a mouse monoclonal antibody when a strong immune response is expected in the mouse spleen.
- the mouse monoclonal antibody against EGF receptor can be allegedly separated from the mouse spleen immunized with A431, a human tumor cell line, by the intra-abdominal injection (Murthy, et al., Arch. Biochem. Biophys . , 252, 549-560, 1987).
- the phage-antibody technique can use any antibody-expressing cell as a starting material, unlike the conventional hybridoma technique, and more over facilitates fast screening of numbers of different antibodies.
- a gene encoding the variable region (V) of the corresponding antibody is already cloned, so that the gene can be used right away for other genetic engineering purposes.
- V H variable region of heavy chain
- V L light chain
- scFv single-chain variable fragment
- V variable region
- the conventional method to produce a monoclonal antibody to EGF receptor using B cells results in low affinity and cross-reactivity.
- the present inventors hire a recombination method using PCR cloning after in vivo immunization.
- mice monoclonal antibody
- HAMA human anti-mouse antibody
- a chimeric antibody has been developed in which mouse variable region (V) is bound to human constant region (C) , and more precisely a humanized antibody has been developed by transplanting some amino acid residues of human framework region (FR) and mouse complementarity determining region (CDR) to a human antibody in order to increase antigen binding capacity (Lobuglio, et al., Proc. Nat. Acad. Sci. USA, 86, 4220-4224, 1989).
- thermo-stability of an antibody plays an important role in targeting of a tumor region (Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun A. Cancer Res. 1999, 59(22) : 5758-5767) .
- Protein aggregates are generally formed by more than one protein molecule, which contains partially or completely denatured molecules. Aggregates cannot be eliminated by filtering or other pre- purification processes because of its homology with biopharmaceuticals.
- Protein aggregation is a huge problem in producing biopharmaceuticals.
- the primary aggregate ratio in the bulk of biopharmaceuticals has to be less than 0.1% and high concentration biopharmaceuticals having at least 100 mg/ml has to be formulated with the acceptable low aggregate content.
- the conventional method to eliminate protein aggregates in the bulk solution is gel filtration, which is to separate aggregates by using the difference in size between aggregates and target monomer proteins.
- this method is not easy to apply to the mass-production of biopharmaceuticals in industry and requires a high cost. Therefore, it is important to select a very stable protein as a lead compound, which doesnot form protein aggregates during cell culture process for the production efficiency and cost reduction.
- a biological drug has an unstable structure or it is apt to generate protein aggregates, it might cause immunogenicity more easily than monomer proteins after being administered in human or the half-life of the drug in blood will be shorten because of the decreased stability in blood.
- targeting efficiency will be significantly reduced because aggregates might be eliminated in the liver or spleen non-specifically.
- the present inventors selected a novel humanized antibody having high stability and high binding capacity to EGF receptor using the recombination technique and then completed this invention by confirming its excellent in vivo/in vitro anticancer effect.
- the present invention provides an EGF receptor specific antibody which comprises a recombinant heavy chain comprising human originated heavy chain constant region (C H ) linked to the heavy chain variable region (V H ) containing rabbit originated heavy chain complementarity determining region (HCDR) and a recombinant light chain comprising human originated light chain constant region (C L ) linked to the light chain variable region (V L ) containing rabbit originated light chain complementarity determining region (LCDR) .
- the present invention also provides a gene encoding the heavy chain variable region of the EGF receptor specific antibody.
- the present invention further provides a gene encoding the light chain variable region specific to the EGF receptor.
- the present invention also provides an expression vector containing the gene encoding the heavy chain of the antibody and an expression vector containing the gene encoding the light chain of the antibody.
- the present invention also provides a transformant prepared by transfecting host cells with the expression vectors .
- the present invention also provides a preparation method of an EGF receptor specific antibody comprising the step of culturing the transformant .
- the present invention also provides a pharmaceutical composition containing the antibody of the invention as an active ingredient for the treatment of malignant tumor over-expressing EGF receptor.
- the present invention also provides a treatment method for malignant tumor over-expressing EGF receptor containing the step of administering the effective dose of the pharmaceutical composition of the invention to a subject.
- the present inventors injected EGF-EGF receptor mixture or epithelial cancer cells to a rabbit to induce immune response. Antibody production therein was confirmed and then total RNA was separated from the bone marrow and spleen of the rabbit. The separated RNA was reverse- transcribed into cDNA. Fab fragments of rabbit variable regions heavy chain (V H ) and light chain (V L ) and human constant region heavy chain (C H i) and light chain (C L ) were amplified by using the above cDNA as a template with a primer set described in the report of Carlos, F.
- each rabbit variable region fragments (V H , V L ) and human constant region fragments (C H i, C L ) were amplified to convert them into ' rabbit V H -human C H i ' and ' rabbit V L -human C L ' using overlapping primers.
- the amplified two fragments were amplified again with those overlapping primers to prepare chimeric Fab having binding capacity to EGF receptor (chimeric antibody binding fragment) .
- the both ends of the chimeric Fab DNA fragment of the library were digested with a restriction enzyme, which was then inserted into pComb3X (Genebank No. AF268281; Rader,C. and Barbas,C.F. III.
- PHAGE DISPLAY A LABORATORY MANUAL. Cold Spring Harbor Laboratory Press, Cold Spring Harbor, NY, USA, 2000
- the present inventors transfected the host cell (ex: ER2738) with the prepared chimeric Fab library to infect helper phage, resulting in the preparation of chimeric Fab phage library.
- Competitive cell panning was performed using the above library to select antibody clones having high binding capacity to EGF receptor.
- Competitive cell panning was performed as follows; cancer cells, membrane fragments of normal fibroblasts, an EGF receptor antibody and the phage library were added and cultured.
- the present inventors amplified the heavy chain and light chain of the chimeric Fab, to which a signal sequence and a restriction enzyme sequence were inserted.
- the amplified products were respectively inserted into pCDH-101 vector expressing human heavy chain cDNA and pCDK-101 vector expressing human light chain (k chain) cDNA (see Fig. 2) .
- the present inventors also investigated the in vitro effect of the antibody of the invention on tumor growth using A431 cells.
- tumor cell growth inhibitory effect (under 40% of relative growth) was confirmed at the antibody concentration of 1 ⁇ g/m#, regardless of the kind of antibodies above (see Fig. 5) .
- the antibody of the invention was also treated to in vivo tumor models.
- tumor cell growth inhibitory effect of CRH4 was greater than that of CRH412 (see Fig. 6), but the effect was not necessarily antibody-dose dependent.
- the present inventors transplanted a sequence containing CDR of CRH412 antibody into hu4D5-framework having comparatively high stability. As shown in Table 4, some amino acids were modified. Then, a novel Fab library transplanted with the CDR was synthesized and CRH412 derivative Fab antibody phage clone binding to EGF receptor was selected by FACS. The DNA sequence of the selected EGF receptor binding clone was analyzed. The selected clones were produced in a whole IgG form. The EGF receptor binding capacity of the novel CRH412 modified antibody was investigated. As a result, the EGF receptor binding capacity of the modified antibodies, except hIgG2 antibody, was equal to that of CRH412 antibody (see Table 6) .
- the present inventors further investigated whether the stability of the novel modified antibodies was improved or not.
- aggregate contents of the novel modified antibodies were investigated. As a result, aggregate content of CRH412 antibody was 7%, while aggregate contents of hIgG2, hIgG12, hIgG18, hIgG2 ⁇ and hIgG32 were all reduced to 1 - 2% (see Fig. 7) .
- thermo-stability of the novel modified antibodies was investigated.
- CRH412 variants exhibited significantly high thermo-stability, compared with a control group, commercial anti-EGFR antibody C255 (Erbitux) (see Fig. 8) .
- the present inventors injected CRH412 and its variants, hIgG12, hIgG18, hIgG19, hIgG26 and hlgG 32, into mouse tumor models.
- the half-life of CRH412 antibody was short in blood and non-specific absorption in the liver and spleen was high.
- CRH412 variants with improved stability exhibited excellent tumor targeting capacity.
- Non-specific absorption in the liver and spleen was reduced and the half-life in blood was increased (see Fig. 9) .
- the present inventors injected hIgG12, hIgG19 and hIgG26, among the CRH412 variants, into mouse tumor models. As a result, they all exhibited excellent tumor suppressing effect (see Fig. 10) .
- the present inventors selected a novel antibody having high affinity and new CDR distinguished from the conventional EGF receptor binding antibodies. And then the inventors prepared a novel antibody with improved stability and thereby excellent in vivo functions and effect.
- the present invention provides an EGF receptor specific antibody which comprises a recombinant heavy chain comprising human originated heavy chain constant region (C H ) linked to the heavy chain variable region (V H ) containing rabbit originated heavy chain complementarity determining region (HCDR) and a recombinant light chain comprising human originated light chain constant region (C L ) linked to the light chain variable region (V L ) containing rabbit originated light chain complementarity determining region (LCDR) .
- the antibody herein is preferably a humanized antibody or a chimeric antibody or its fragment.
- the heavy chain complementarity determining region is preferably a humanized antibody or a chimeric antibody or its fragment.
- CDR preferably includes CDR-Hl represented by SEQ. ID.
- the light chain complementarity determining region preferably includes CDR-Ll represented by one of SEQ. ID.
- the heavy chain variable region herein is preferably selected from the group consisting of the sequences represented by SEQ. ID. NO: 33 - NO: 56, and the light chain variable region herein is preferably selected from the group consisting of sequences represented by SEQ. ID.
- variable region herein indicates a part of an antibody that has an antigen specific binding capacity and various mutations in its sequence, which includes CDRl,
- the complementarity determining region is a ring shaped region involved in recognition of an antigen and the specificity of an antibody against an antigen depends on the sequence of this region.
- some parts of CDR and the amino acids of the framework were modified with human immunoglobulin originated sequences to prepare a humanized antibody having high stability without damaging its EGF receptor binding capacity.
- variable region containing CDR can be easily modified without losing its binding capacity to EGF receptor.
- the modified sequence competes with CRH412 to bind EGF receptor and it can be included in the present invention as long as it has higher stability than CRH412.
- the stability can be measured by various ways such as binding capacity before and after heat treatment, aggregate content and tumor tissue targeting, etc.
- the ⁇ antibody' of the invention includes not only a whole antibody but also a functional fragment of an antibody.
- the whole antibody is composed of two full length light chains and two full length heavy chains and each light chain is linked to each heavy chain by disulfide bond.
- the functional fragment of an antibody indicates a fragment that has an antigen-binding capacity, which is exemplified by (i) a Fab fragment composed of light chain variable region (VL) , heavy chain variable region (VH) , light chain constant region (CL) and the first constant region of heavy chain (CHl); (ii) a Fd fragment composed of VH and CHl domains; (iii) a Fv fragment composed of VL and VH domains;
- a dAb fragment composed of VH domain (Ward, E. S. et al., Nature 341: 544-546, 1989); (v) an isolated CDR region; (vi) a F(ab')2 fragment composed of two linked Fab fragments; (vii) a single chain Fv molecule (ScFv) in which VH domain and VL domain are bound by a peptide linker to form an antigen binding site; (viii) a bi-specific single chain Fv dimmer (PCT/US92/09965) and (ix) a multivalent or multi-specific fragment diabody (9WO94/13804) prepared by gene fusion.
- the antibody is preferably a whole antibody or a Fab fragment.
- the humanized antibody or chimeric antibody provided by the invention can be linked to any constant region by the recombination technique.
- the heavy chain variable region has ⁇ , ⁇ , ⁇ , ⁇ and ⁇ types and the light chain variable region has K and ⁇ types.
- IgGl type antibody is preferably used in the invention.
- the present invention also provides a gene encoding the heavy chain variable region of the EGF receptor specific antibody.
- the gene preferably comprises a nucleic acid sequence encoding the heavy chain variable region containing CDR-Hl represented by SEQ. ID. NO: 19, CDR-H2 represented by SEQ. ID. NO: 20 and CDR-H3 represented by SEQ. ID. NO: 21 or NO: 22.
- a nucleic acid sequence encoding the heavy chain variable region represented by one of SEQ. ID. NO: 33 - NO: 56 is more preferred.
- the invention provides a nucleic acid sequence encoding the heavy chain variable region H19 of the antibody hIgG19.
- nucleic acid sequences encoding the various heavy chain variable regions can be easily prepared by substituting codons encoding a couple of amino acids based on the sequence represented by SEQ. ID. NO: 85, according to the conventional method well-known to those skilled in the art.
- the present invention further provides a gene encoding the light chain variable region specific to EGF receptor.
- the gene preferably comprises a nucleic acid sequence encoding the light chain variable region containing CDR-Ll represented by one of SEQ. ID. NO: 23 - NO: 26, CDR-L2 represented by one of SEQ. ID. NO: 27 - NO: 29 and CDR-L3 represented by one of SEQ. ID. NO: 30 - NO: 32. It is more preferably a nucleic acid sequence encoding the light chain variable region represented by one of SEQ. ID. NO: 57 - NO: 84.
- the invention provides a nucleic acid sequence encoding the light chain variable region Ll9 of the antibody hIgG19.
- nucleic acid sequences encoding the various light chain variable regions can be easily prepared by substituting codons encoding a couple of amino acids based on the sequence represented by SEQ. ID. NO: 86, according to the conventional method well-known to those skilled in the art.
- the present invention also provides an expression vector containing the gene encoding the heavy chain variable region of the antibody.
- pCDH-101 of Fig. 2 it is preferred to use pCDH-101 of Fig. 2 as a mother vector for the expression vector, but not always limited thereto.
- the present invention also provides an expression vector containing the gene encoding the light chain variable region of the antibody. It is preferred to use pCDK-101 of Fig. 2 as a mother vector for the expression vector, but not always limited thereto.
- the present invention also provides a transformant prepared by transfecting host cells with the expression vectors containing the heavy chain region and the light chain region genes.
- the host cells herein can be prokaryotic cells such as E. coli or Bacillus subtilis or eukaryotic cells such as yeast like Saccharomyces cerevisiae, insect cells, plant cells or animal cells.
- the host cells can be selected from the group consisting of mouse myeloma cells, CHO cells, monkey kidney cells (COSl, C0S7, etc), NSO cells, SP2/0 cells, W138 cells, BHK cells, Namalwa cells, BALL-I cells, JBL cells and 293 cells, but not always limited thereto.
- the introduction of the expression vector to the host cell is performed by any conventional method known to those skilled in the art.
- the present invention also provides a preparation method of an EGF receptor specific antibody comprising the steps of (1) culturing the transformant; and (2) purifying an antibody from the culture solution.
- the culture medium can be any of those appropriate for the transformant which has been well-known to those skilled in the art.
- the antibody purification can be performed by one of the conventional methods known to hooc those skilled in the art.
- the host cells herein can be prokaryotic cells such as E. coli or Bacillus subtilis or eukaryotic cells such as yeast like Saccharomyces cerevisiae, insect cells, plant cells or animal cells.
- the host cells can be selected from the group consisting of mouse myeloma cells, CHO cells, monkey kidney cells (COSl, C0S7, etc), NSO cells, SP2/0 cells, W138 cells, BHK cells, Namalwa cells, BALL-I cells, JBL cells and 293 cells, but not always limited thereto.
- the tissue is preferably bone marrow or spleen, but not always limited thereto.
- the present invention also provides a pharmaceutical composition containing the antibody of the invention as an active ingredient for the treatment of malignant tumor over-expressing EGF receptor.
- the present inventors investigated the tumor cell growth inhibitory effect of the whole IgG chimeric antibody of the invention in human tumor models using the method described in Ishiyama's paper (Ishiyama, et al., Biol,
- the chimeric antibody of the invention was treated to the nude mouse tumor model and the tumor inhibitory effect was measured.
- the selected chimeric antibody suppressed the growth of A431 epidermoid carcinoma cell line, compared with the negative control.
- the present inventors treated CRH412 antibody and its variants with improved stability, hIgG12, hlgGl ⁇ , hIgG19, hIgG26 and hIgG32 to mouse tumor models.
- CRH412 antibody exhibited short half-life in blood and high level of non-specific absorption in the liver and spleen.
- the CRH412 variants with improved stability exhibited excellent tumor targeting and decreased non-specific absorption in the liver and spleen and increased half-life in blood (see Fig. 9) .
- hIG12, hIgG19 and hIgG26 among the CRG412 variants showed excellent tumor suppressing activity in mouse tumor models (see Fig. 10).
- EGFR is over expressed in many different cancers including breast cancer, colon cancer, lung cancer and head/neck cancer (Ullrich et al., Endocrine-related cancer, 8, 11-31, 2001). Therefore, the pharmaceutical composition of the present invention can be effectively used for the treatment of such cancers overexpressing EGFR shown in Table 1.
- the effective dose of the pharmaceutical composition of the invention is preferably the concentration of serum of the antibody enabling EGF receptor saturation. For example, more than 0.1 nM is considered to be enough.
- the composition includes the chimeric antibody, the humanized antibody or the transformant as an active ingredient.
- the pharmaceutical composition of the present invention can additionally include one or more active ingredients having the same or similar functions to the active ingredient of the invention.
- the composition of the present invention can also include, in addition to the above-mentioned effective ingredients, one or more pharmaceutically acceptable carriers for the administration.
- the pharmaceutically acceptable carrier can be selected or be prepared by mixing more than one ingredients selected from the group consisting of saline, sterilized water, Ringer' s solution, buffered saline, dextrose solution, maltodextrose solution, glycerol and ethanol. Other general additives such as anti-oxidative agent, buffer solution, bacteriostatic agent, etc, can be added. In order to prepare injectable solutions, pills, capsules, granules or tablets, diluents, dispersing agents, surfactants, binders and lubricants can be additionally added.
- the composition of the present invention can further be prepared in suitable forms for each disease or according to ingredients by following the method represented in Remington' s
- the pharmaceutical composition of the present invention can be administered orally or parenterally (for example, intravenous, hypodermic, local or peritoneal injection) . But, intravenous injection is preferred. To treat a solid tumor, local administration would be preferred because it is important for the antibody to reach the solid tumor fast and easy.
- the effective dosage of the composition can be determined according to weight, age, gender, health condition, diet, administration frequency, administration method, excretion and severity of a disease.
- One time dose of the chimeric antibody, the humanized antibody or the transformant is approximately 5 - 500 mg/m 2 , which can be administered every day basis or every week basis. In the case of the antibody fragment, the administration has to be more frequent in order to keep serum to maintain EGF receptor level as saturation.
- composition of the present invention can be administered singly or treated along with surgical operation, hormone therapy, chemotherapy and biological reaction regulator, to prevent and treat malignant tumor.
- the malignant tumor over-expressing EGF receptor that can be treated with the pharmaceutical composition of the invention is preferably selected from the group consisting of breast cancer, bladder cancer, colon cancer, glioma, non-small-cell lung cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, salivary cancer and head/neck cancer.
- the present invention also provides a treatment method for malignant tumor over-expressing EGF receptor containing the step of administering the effective dose of the pharmaceutical composition of the invention to a subject .
- the malignant tumor over-expressing EGF receptor above is preferably selected from the group consisting of breast cancer, bladder cancer, colon cancer, glioma, non- small-cell lung cancer, pancreatic cancer, ovarian cancer, stomach cancer, lung cancer, salivary cancer and head/neck cancer.
- the effective dose can be determined by a doctor in charge.
- Fig. 1 is a diagram illustrating the amino acid sequences of heavy chains and light chains (K chains) of 7 antibodies binding to EGF receptor.
- Fig. 2 is a diagram illustrating the antibody expression vector for the preparation of a whole IgG.
- Fig. 3 is a diagram illustrating the result of SDS- PAGE with antibodies binding to the EGF receptor expressed, separated and purified from CHO cells.
- Fig. 4 is a graph illustrating the EGF binding capacity of antibodies, measured by ELISA.
- Fig. 5 is a graph illustrating the in vitro inhibition of cell growth of a human epidermoid carcinoma cell line A431 by the selected antibody.
- Fig. 6 is a graph illustrating the tumor sizes (mm 3 ) in mouse models transplanted with tumor cells to examine the effect of the antibody.
- Fig. 7 is a diagram illustrating the result of the investigation of aggregate content, measured by SEC-HPLC.
- Fig. 8-1 is a diagram illustrating the maintenance of the binding capacity to EGF receptor after heat treatment, measured by ELISA.
- Fig. 8-2 is a diagram illustrating the changes of aggregate content after heat-treatment, measured by SEC- HPLC.
- Fig. 9 is a diagram illustrating the in vivo distribution of the antibody in a mouse tumor model.
- Fig. 10 is a graph illustrating the tumor sizes in mouse tumor models to investigate the effect of the antibody.
- Example 1 Construction of chimeric Fab library
- EGF receptor specific chimeric Fab (chimeric antibody binding fragment) library a recombinant EGF and EGF receptor protein mixture or epidermoid carcinoma cells (A431; ATCC, CRL-1555) were mixed with Ribi adjuvant (Sigma Co.) at the ratio of 1:1. This mixture was injected into a rabbit at three week intervals to induce immune response. Blood samples ⁇ were taken from the immunized rabbit (immunized by four times of injection) and antibody formation was confirmed. Total RNA was extracted from the bone marrow and spleen of the rabbit, which was reverse-transcribed into cDNA using Superscript II kit (Invitrogen) .
- the rabbit variable region heavy chain (V H ) and light chain (V L ) were amplified using the above cDNA as a template with the primer set described in the paper of Carlos, F (Phage Display: A Laboratory Manual, Carlos, F. et al., 2001 by Cold Spring Harbor Laboratory Press, Volume 1) .
- the Fab fragments of the human constant region heavy chain (C HI ) and light chain (C L ) were also amplified with the same primer set.
- the amplified rabbit variable region fragments (V H , V L ) and human constant region fragments (C HI , CL) were amplified to convert them into 'rabbit V H -human C HI ' and 'rabbit V L -human C L ' using overlapping primers.
- the amplified two fragments were amplified again with those overlapping primers to prepare chimeric Fab DNA.
- the chimeric Fab library constructed in the above example was introduced into ER2738 cells (New England
- Plasmid DNA was separated from the cells collected from the centrifugation. Polyethylene glycerol (PEG) was added to the supernatant, which proceeded to centrifugation to obtain a pellet. The pellet was suspended in reaction buffer supplemented with 1% BSA and 0.02% sodium azide.
- PEG Polyethylene glycerol
- the phage was recovered to prepare chimeric Fab phage library.
- Example 3 Amplification of EGFR binding chimeric Fab antibody phage pool
- reaction mixture was centrifuged to obtain a pellet, which was washed four times with reaction buffer supplemented with 0.1% Tween 20. 1 ml of 100 mM TEA was added thereto, followed by culture at 37 ° C for 10 minutes to elute the phage. The eluted phage solution was neutralized with 1 M Tris (pH 7.4). 1 ml of the neutralized solution was mixed with 10 ml of ER2738 cell solution (OD 6 oo: - 1) i followed by culture for one hour. Helper phage was added to the culture solution, followed by further culture for 16 - 19 hours.
- Example 4 Selection of the chimeric Fab phage highly binding to EGFR
- A431 cells were treated with dissociation buffer (GIBCO) and then detached from the plate. After washing three times with PBS, the cells were suspended in FACS (1% BSA, 0.02% sodium azide, PBS) at the concentration of 5 ⁇ lO 5 cell/ml, which were distributed in a 96-well v bottom plate (Corning, #3897) by 200 ⁇ £/well. The plate was incubated at 4 ° C for one hour, followed by centrifugation to remove supernatant.
- FACS 1% BSA, 0.02% sodium azide, PBS
- the phage pool prepared in example 3 was distributed in the plate, followed by culture at 37 "C for overnight to obtain colonies.
- the obtained colonies were inoculated in SB medium (Beckton Dickenson) , which was then infected with helper phage by the same manner as described in example 3.
- the resultant phage was added to the plate by 100 / ⁇ /well, followed by culture at 4°C for one hour. After washing with FACS solution twice, 50 ⁇ & of anti-Fab FITC antibody
- Example 5 Construction of an expression vector for whole IgG production from chimeric phage antibody and the expression thereof in 293T/17 cells
- Example 4 as a whole IgG form, the heavy chain variable region of the chimeric Fab was amplified, to which a signal sequence was inserted. Restriction enzyme recognition sites ⁇ Eco RI and Apa I) were also inserted in both ends.
- the first PCR was performed using the phagemid DNA obtained from the chimeric Fab phage clone as a template with primers C4H_Fwl (SEQ. ID. NO: 3) and C4H_Rvl (SEQ. ID. NO: 4), the second PCR was performed using the first PCR product as a template with primers C4HK_Fw2 (SEQ. ID. NO: 5) and C4H_Rv2 (SEQ. ID. NO: 6), and the third PCR was performed using the second PCR product as a template with primers C4H_Fw3 (SEQ. ID. NO: 7) and C4H_Rv2 (SEQ. ID. NO: 8).
- PCRs were performed using DNA polymerase (Taq polymerase, Takara) as follows; predenaturation at 94 ° C for 5 minutes, denaturation at 94 ° C for 1 minute, annealing at 55 ° C for 1 minute, polymerization at 72 ° C for 1 minute, 30 cycles from denaturation to polymerization, and final extension at
- variable region of the pCDH-101 vector expressing human heavy chain cDNA was digested with Eco RI and Apa I, to which the third PCR product digested with Eco RI and Apa I was cloned.
- the resulted expression vectors were named as pCDH-4, pCDH-44, pCDH-46, pCDH-47, pCHD-49, pCDH-H411 and pCDH-412.
- the light chain (K chain) variable region of the chimeric Fab phage was amplified, to which a signal sequence was inserted and so were Hind III and Bsiw I restriction enzyme sites in both ends.
- the first PCR was performed using the phagemid DNA obtained from the chimeric Fab phage clone as a template with primers C4K_Fwl (SEQ. ID. NO: 8) and C4K_Rvl (SEQ. ID. NO: 9)
- the second PCR was performed using the first PCR product as a template with primers C4HK_Fw2 (SEQ. ID. NO: 5) and C4K_Rvl (SEQ. ID. NO: 9)
- the third PCR was performed using the second PCR product as a template with primers C4K_Fw3 (SEQ. ID. NO: 10) and C4K_Rvl (SEQ. ID. NO: 9) .
- variable region of the pCDK-101 expressing chimeric light chain (K chain) cDNA was digested with Hind III and Bsiw I, to which the third PCR product digested with Hind III and Bsiw I was inserted.
- the resultant expression vectors were named as pCDK-4, pCDK-44, pCDK-46, pCDK-47 pCDK-49, pCDK-411 and pCDK-412.
- CDR complementarity determining region
- the present inventors prepared an antibody as a whole IgG form by introducing the expression vectors produced above into animal cells.
- the heavy chain and light chain expression vectors pCDH-X and pCDK-X were mixed at the ratio of 3: 7 (to form a whole antibody with a set of one heavy chain and one light chain that have same number) , which was introduced into 293T/17 cells
- the transformant was cultured in HYQ SFM4CH0 medium
- Example 6 Binding capacity ⁇ 6-l> BIAcore analysis
- the affinity constant of the purified antibody to EGF receptor was determined by BIAcore analysis.
- BIAcore 3000 was used for the analysis.
- ELISA The binding capacity of the IgG antibody purified in Example 5 to the recombinant human EGF receptor (R&D systems) was measured in vitro by ELISA. Particularly, the EGF receptor was loaded in each well of a 96-well plate at the concentrations of 300 ng/ml and 1 fig/ml, followed by coating at 4 "C for 16 hours or at 37 ° C for 3 hours. Then, the plate was washed three times with TBST supplemented with 0.05% Tween 20.
- the IgG antibody was serially diluted, 5- fold each time (1526.5 ng/ml - 0.1 ng/ml) , which was distributed in the 96-well plate, followed by conjugation incubation at 37 ° C for 1 hour.
- the plate was washed three times with 0.05%-TBST, to which HRP labeled goat anti-human IgG (Fc, Sigma) secondary antibody diluted 3000 fold in 2% BSA-TBST was added, followed by incubation at 37 °C for one hour. After washing three times with 0.05%-TBST, color development was induced at 37 ° C for 7 minutes with OPD (OPD (O-Phenylenediamine dihydrochloride, Sigma) . The reaction was terminated by
- CRH44, CRH46, CRH47, CRH49, CRH411 and CRH412 showed higher binding capacity than that of CRH4 antibody (Fig. 4) .
- the cells (2*10 3 ) were diluted in 200 j ⁇ medium, which were inoculated in a 96-well plate, to which the chimeric antibody diluted in 100 ⁇ i medium was added, followed by culture at 37 ° C for 3 - 5 days.
- a control was prepared without adding the antibody of the present invention but cultured under the same condition.
- the cells were fixed with 0.25% glutaraldehyde, washed with 0.9% NaCl solution and dried at room temperature. The cells were stained with 0.4% crystal violet, washed with water and dried at room temperature. 100 ⁇ l of methanol was added thereto, followed by mixing at room temperature for 5 minutes. Then, OD 595 was measured. The relative cell growth was calculated by comparing the cell growth of the experimental group with that of the control group added with a medium without antibodies, which was presented as %.
- A431 cells cultured in the serum free medium exhibited the relative growth of less than 40% at the antibody concentration of 1 //g/ml, suggesting that the tumor cell growth inhibitory • effect of the antibody was confirmed (Fig. 5) .
- Example 8 In vivo anticancer effect in mouse tumor models
- balb/c nude mouse tumor models were used.
- an epidermoid carcinoma cell line (A431; ATCC, CRL-1555) was used as a cell line for tumor transplantation.
- the A431 cells (5 ⁇ lO 6 ) in 100 ⁇ i buffer were transplanted into the abdominal region of balb/c nude mice by hypodermic injection.
- the tumor size reached 100 mm 3
- the mice were grouped randomly and then administered with the antibody through intra-abdominal cavity at different concentrations and different frequencies. Then, the tumor growth was observed over time and concentrations.
- the tumor growth inhibitory effect of CRH4 antibody in A431 cells was observed even at low concentration of 0.1 mg, which was not much different from the effect at the concentration of 0.5 mg.
- the tumor growth inhibitory effect continued approximately 7 days until the tumor was grown to 500 mm 3 .
- CRH4 and CRH412 antibodies were compared.
- the tumor growth inhibition by CRH4 antibody was significant.
- the tumor growth inhibitory effect continued approximately 21 days until the tumor was grown to 500 mm 3 .
- the tumor growth inhibition by CRH412 was not significant, which was similar with that in the negative control.
- a sequence containing CDR (complementary determining region) of the CRH412 antibody was transplanted into hu4D5-framework (referred as "4D5" hereinafter; Willuda J, Honegger A, Waibel R, Schubiger PA, Stahel R, Zangemeister-Wittke U, Pluckthun A. Cancer Res. 1999, 59 (22) :5758-5767) which has been known to have high stability.
- each light chain and. heavy chain variable region (VK, VH) was synthesized by PCR using oligo nucleotide.
- the synthesis was performed by the method described in the paper of Gao, et al (Gao X, Yo P, Keith A, Ragan TJ, Harris TK. Nucleic Acids Res. 2003; 31 (22) :el43. ) , and the synthetic oligo nucleotide was designed by DNAWorks 3.1 program (http: //helixweb.nih. gov/dnaworks/) .
- the synthesized VK sequence and VH sequence were inserted into the vector pComb3X (GeneBank No. AF268281) for phage display by the same manner as described in Example 1.
- a Fab phage library was constructed by the same manner as described in Example 2.
- Example 10 Selection of CRH412 derivative Fab antibody phage clone binding to EGF receptor Epoxy bead panning was performed to selectively amplify the EGFR binding antibody pool using the novel CRH412 Fab phage library constructed in Example 9.
- the phage library (4 ⁇ 10 12 /ml) was mixed with the epoxy bead (l*10 7 , Dynal) coated with BSA, followed by reaction at 4 ° Cfor one hour.
- the epoxy bead coated with the recombinant EGFR extra cellular domain (EGFR ECD) was suspended in reaction buffer supplemented with 1% BSA and 0.02% sodium azide, followed by reaction at 4 ° C for one hour.
- the EGFR ECD coated bead and the phage library were recovered and mixed, followed by culture at 4 ° C for 2 hours.
- the bead was collected from the reaction mixture using a magnet and washed four times with reaction buffer supplemented with 0.1% Tween 20, to which dilution buffer (0.1 M citrate, pH 3.1) was added. After culturing at room temperature for 10 minutes, the phage was eluted. The phage eluate was neutralized with 1 M Tris (pH 8.0), from which 1 ml was taken and mixed with 20 ml of XLl-blue cells (OD ⁇ oo: - 1) t followed by culture for one hour. Helper phage was added thereto, followed by further culture for 16 - 19 hours. Upon completion of the culture, centrifugation was performed to obtain supernatant. After adding PEG, centrifugation was performed again to precipitate the phage. The precipitated phage was collected and used for panning. The above panning was repeated three times and at last the phage pool was obtained.
- dilution buffer 0.1 M citrate, pH 3.1
- FACS analysis was performed to select an individual antibody clone binding specifically to EGF receptor from the Fab phage pool.
- the culture medium RPMI, 10% FBS
- the cells were detached from the plate by treating dissociation buffer (GIBCO) , washed with PBS three times, suspended in FACS solution (1% BSA, 0.02% sodium azide, PBS) at the concentration of 5 ⁇ lO 5 cell/ml, distributed in a 96-well V-bottom plate (Corning, #3897) at the concentration of 200 /z ⁇ /well and cultured at 4 ° C for one hour. Centrifugation was performed to eliminate supernatant.
- the phage pool obtained in the above was distributed on the plate, followed by culture at 37 ° C for one day and then colonies were collected.
- the colonies were inoculated to SB medium (Beckton Dickenson) , which was infected with helper phage by the same manner as described in Example 2.
- the obtained phage was added to the plate by 100 ⁇ -C/well, followed by culture at 4 ° C for one hour.
- 50 ⁇ i of anti-Fab FITC antibody FITC-conjugated anti-Human IgG, F(ab ⁇ )2 fragment specific, Jackson ImmnoRese
- the culture solution was washed with FACS solution three times and then washed once again with reaction buffer, followed by FACS to select phage clones binding to A431 cells expressing EGF receptor.
- DNA sequence of the selected clones binding to A431 EGFR was analyzed and as a result the antibody clones having the amino acid sequences shown in Fig. 7 were obtained.
- Example 11 Construction of an expression vector for the preparation of a whole IgG from a humanized phage antibody and the expression thereof in 293T/17 cells
- Example 10 was prepared as a whole IgG form by the same method as described in Example 5.
- the heavy chain variable region and constant region of the Fab phagemid DNA were amplified, to which a signal sequence was inserted and so were restriction enzyme sites (Eco RI and Age I) into the both ends.
- the first PCR was performed by using the phagemid DNA obtained from the Fab phage clone of Example 10 as a template with primers hH_Fw and Heavy_CHl_Rev.
- Amplification of the signal sequence was performed by using the pCHD-101 vector DNA as a template with primers CMV_Fw and C4_0v_Rv
- the second PCR was performed by using the first PCR product as a template with primers CMV_Fw and Heavy_CHl-Rev.
- PCRs were performed using DNA polymerase (High fidelity Taq polymerase, Roche) as follows; predenaturation at 95 ° C for 5 minutes, denaturation at 95°C for 45 seconds, annealing at 56 ° C for 45 seconds, polymerization at 72 ° C for 2 minutes, 15 cycles from denaturation to polymerization, and final extension at 72 ° C for 10 minutes.
- DNA polymerase High fidelity Taq polymerase, Roche
- the light chain (K chain) variable region of the Fab phagemid DNA was amplified, to which a signal sequence was inserted and so were restriction enzyme sites ⁇ Hind III and Bsi WI) into the both ends.
- the first PCR was performed by using the phagemid DNA obtained from the Fab phage clone of Example 10 as a template with primers hL_Fwl/2 and hL_Rvl/2.
- Amplification of the signal sequence was performed by using the pCHD-101 vector DNA as a template with primers CMV_Fw and C4_0v_Rv
- the second PCR was performed by using the first PCR product as a template with primers CMV_Fw and hL_Rvl/2.
- the variable region of the vector pCDK-101 expressing human light chain (K chain) cDNA was digested with Hind III and Bsi WI, to which the PCR product digested with Hind III and Bsi WI was inserted.
- IgG expression vector prepared above was inserted into animal cells by the same manner as described in Example 5 and IgG was purified therefrom.
- Example 12 EGF receptor binding capacity of the novel CRH412 modified antibody
- hIgG2 is the antibody composed of the heavy chain variable region H2 and the light chain variable region L2 as shown in Fig. 7, and other antibodies were composed of the heavy chain and the light chain having same numbers by the same manner.
- the novel CRH412 modified antibodies were confirmed to have the same level of EGF receptor binding capacity with CRH412, except hIgG2 (Table 6) .
- Example 13 Improvement of the stability of the antibody ⁇ 13-1> Analysis of the aggregate content of the antibody
- CRH412 antibody and its variants were purified by protein-A column and the size of the purified antibody was measured by Size Exclusion Chromatography (SEC) HPLC. Particularly, two TSK-GELG300OSWXL columns were connected in series, over which the elution buffer (150 mM NaCl, 200 mM KPO 4 , pH 6.9) was flowing and OD was measured at 280 nm and at 220 nm.
- SEC Size Exclusion Chromatography
- thermo-stability of the antibody 100 ⁇ i of each CRH412 and CRH412 modified antibodies (1.56 ⁇ g/ml) respectively was loaded in a microtube, followed by heat treatment at 80°C for 10 minutes. After the heat- treatment, centrifugation was performed at 13,000 rpm for 10 minutes. The obtained supernatant was filtered with a 0.22 ⁇ m filter and the filtrate was diluted serially in PBS + 0.1% BSA solution, 5 fold each time, followed by EGFR binding ELISA.
- ELISA was performed as follows; each well of a 96-well plate was coated with 300 ng/ml of EGF receptor at 4°C for 16 hours, and then washed three times with TBST (Tris-Buffered Saline Tween 20) supplemented with 0.05% Tween 20.
- TBST Tris-Buffered Saline Tween 20
- IgG antibody was diluted serially in 2% BSA-TBST, 5 fold each time (1526.5 ng/ml - 0.1 ng/ml), and the solution was distributed in a 96-well plate, followed by conjugation at 37 °C for 1 hour.
- the plate was washed three times with 0.05%-TBST, followed by conjugation with HRP (Horse radish peroxidase) labeled goat anti-human IgG (goat anti-human Fc, Sigma) secondary antibody diluted 3000-fold in 2% BSA-TBST at 37 ° C for 1 hour. After washing three times again with 0.05%- TBST, color development was induced with OPD (O- Phenylenediamine dihydrochloride, Sigma) at 37 " C for 7 minutes. The reaction was terminated by 2.5 N sulfuric acid and then OD4 90 was measured.
- the C225-control indicates the binding capacity of C225 before the heat-treatment and others indicate the clone specific binding capacity of C225
- EGF receptor binding capacities of C225 and CRH412 were significantly reduced to 0% after the heat treatment.
- EGF receptor specific binding capacities of the CRH412 variants were not reduced after the heat-treatment and maintained the EGF receptor binding capacity level to the equal level of C225 not treated with heat.
- thermo-stability of the antibody was performed as follows; 50 ⁇ l of each C225 (Erbitux) , CRH412 and CRH412 modified antibodies were loaded in a microtube respectively at the concentration of 2 mg/ml, followed by heat-treatment at 65 ° C for 10 minutes. After the heat-treatment, 40 ⁇ g of each antibody proceeded to SEC (size exclusion chromatography) by the same manner as described in Example ⁇ 13-1>. In case of the C225 antibody, the aggregate content after the heat treatment (65°C, 10 minutes) was approximately 12%.
- hIgG2 the aggregate contents of hIgG2, hIgG12, hlgGl ⁇ , hIgG19, hIgG2 ⁇ and hIgG32 were all less than 1% of total protein, suggesting that they were all very stable antibodies.
- C225 Erbitux
- CRH412 variants were confirmed to have excellent thermo-stability.
- Fig. 8-2 illustrates the result of comparison of the thermo-stability between hIgG26 and C225.
- CRH412 antibody and hIgG12, hlgGl ⁇ , hIgG19, hIgG26 and hIgG32 antibodies were labeled with DOTA-linker and then labeled again with 11:L Indium.
- the labeled antibodies were intravenously-injected into the tail vein of the xenograft nude mouse transplanted with A431 cells. After 24 hours and 48 hours from the injection, the test animals were sacrificed and each organ was extracted and radioactivity was measured. Compensating the natural decay of radioactivity at each check point, the in vivo distribution was presented by %ID (Injected Dose) per gram tissue.
- DOTA-linker as follows. 460 fd (460 ⁇ g, 666.7 nmol) of p-SCN-Bn-D0TA[2- (4- Isothiocyanatobenzyl) -1, 4,7, 10-tetraazacyclo dodecane- 1, 4, 7, 10-tetraacetic acid] at 1 mg/ml concentration (in 0. IM Sodium bicarbonate, pH 8.7) was added to 1 mg/200 ⁇ i of each CRH412 (experimental antibody) and C225 (control antibody) , followed by reaction at 37 ° C for 60 minutes in the dark.
- PD-IO column was loaded with 1% BSA and 1 ml of 20 mM cold DOTA and then fully washed with DDW (deionized distilled water) .
- the DOTA binding antibody was loaded into the PD- 10 column, followed by fractionation by 0.5 ml using 0.9% NaCl (in DDW, ultra pure reagent) .
- the DOTA binding antibody was aliquoted by 50 ⁇ g (approximately 1 mg/2 ml) , which was stored at -70 ° C.
- 1:L1 Indium labeling was performed as follows. 50 ⁇ g of the DOTA binding antibody was mixed with 200 ⁇ i of 0.1 M sodium acetate (pH 5.4, reaction solution), to which 500 ⁇ Ci of 1:L1 Indium was added, followed by reaction for one hour at room temperature. PD-10 column was loaded with 1 ml of 1% BSA, followed by washing with injectable saline. The 11:L In-DOTA-antibody was loaded into the PD-10 column, followed by fractionation by 0.5 ml using 0.9% NaCl (in DDW, ultra pure reagent) . Radioactivity of the fraction was measured.
- A431 xenograft model was generated as follows. A431 cells (5* 10 6 ) were added into 100 ⁇ i of buffer, which was transplanted into the abdominal region of balb/c nude mice by hypodermic injection. When the tumor size reached 100 mm 3 , the mice were grouped randomly. 8 of each group were injected intravenously with 5 ⁇ Ci of the 111 In labeled antibody into the tail vein. After 24 and 48 hours from the injection, 4 of each group were sacrificed and the in vivo distribution of the antibody was examined. The organs such as blood, liver, spleen, kidney, muscle, skin, bone, lung, heart, stomach, brain, tumor, intestine, and tail were extracted and the radioactivity therein was measured.
- CRH412 and its modified antibodies with improved stability after Indium-Ill labeling were shown in Fig. 9.
- the CRH412 antibody showed very weak tumor targeting of 2 ⁇ 1 %ID/g and 2+1 %ID/g respectively at 24 th and 48 th hour from the labeling.
- the CRH412 also exhibited short half-life in blood and high non-specific absorption in the liver and spleen.
- K 0 3.90E-11 M.
- the modified antibodies with improved stability exhibited excellent tumor targeting.
- those variants exhibited very low non-specific absorption in the liver and spleen and increased half-life in blood.
- the anti-EGF receptor antibody of the present invention has high binding capacity to EGF receptor, so that it can inhibit EGF binding and has excellent tumor suppressing effect and tumor targeting with high stability. And also, the anti-EGF receptor antibody can minimize immune response against the antibody by containing human immunoglobulin constant regions, so that it can be effectively used for the diagnosis and treatment of cancer expressing EGF receptor.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Life Sciences & Earth Sciences (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La présente invention concerne un anticorps humanisé présentant une excellente stabilité et une grande capacité de liaison au récepteur de facteur de croissance épidermique (EGFR), plus précisément un anticorps humanisé constitué d'une région de détermination de complémentarité (CDR) dérivée d'un lapin immunisé et une région de charpente dérivée d'immunoglobuline humaine. L'anticorps humanisé selon la présente invention présente une grande capacité de liaison au récepteur EGF et assure ainsi l'inhibition de liaison au EGF et accroît la stabilité, entraînant un effet de suppression tumorale in vivo. En outre, l'anticorps humanisé minimise la réponse immunitaire de sorte qu'il peut être utilisé efficacement pour le diagnostic et le traitement du cancer surexprimant le récepteur EGF.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR20060063541 | 2006-07-06 | ||
KR10-2006-0063541 | 2006-07-06 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2008004834A1 true WO2008004834A1 (fr) | 2008-01-10 |
Family
ID=38894758
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/KR2007/003294 WO2008004834A1 (fr) | 2006-07-06 | 2007-07-06 | Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2008004834A1 (fr) |
Cited By (22)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008136694A1 (fr) | 2007-05-04 | 2008-11-13 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Domaines variables transgéniques d'anticorps de lapin et leurs utilisations |
WO2009155726A2 (fr) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanisation d'anticorps de lapins au moyen d'une infrastructure d'anticorps universelle |
WO2012143495A2 (fr) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Nouveaux conjugués liant-principe actif (adc) et leur utilisation |
WO2013056851A2 (fr) | 2011-10-20 | 2013-04-25 | Esbatech - A Novartis Company Llc | Anticorps stable se liant à de multiples antigènes |
US8545849B2 (en) | 2010-10-22 | 2013-10-01 | ESBATech, an Aclon Biomedical Research Unit LLC | Stable and soluble antibodies |
US8673310B2 (en) | 2008-06-25 | 2014-03-18 | ESBA Tech, an Alcon Biomedical Research Unit LLC | Stable and soluble antibodies inhibiting TNFα |
WO2014206561A1 (fr) | 2013-06-26 | 2014-12-31 | Numab Ag | Structures d'anticorps |
JP2015120746A (ja) * | 2008-06-25 | 2015-07-02 | エスバテック − ア ノバルティスカンパニー エルエルシー | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
AU2013203004B2 (en) * | 2008-06-25 | 2016-09-08 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
WO2016207089A1 (fr) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Conjugués anticorps-médicament (adc) et conjugués lieur-promédicament (apdc) à groupes enzymatiquement clivables |
WO2017060322A2 (fr) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Conjugué anticorps-médicament (adc) inhibiteur de ptefb |
WO2017162663A1 (fr) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Promédicaments de principes actifs cytotoxiques contenant des groupes fissibles par voie enzymatique |
JP2017192384A (ja) * | 2009-02-24 | 2017-10-26 | エスバテック − ア ノバルティス カンパニー エルエルシー | 細胞表面抗原のイムノバインダーを同定するための方法 |
WO2018114798A1 (fr) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Promédicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique |
WO2018114578A1 (fr) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Conjugués liant-principe actif (adc) ayant des groupes enzymatiquement clivables |
US10022453B2 (en) | 2013-12-23 | 2018-07-17 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
EP3459968A1 (fr) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Nouvelles combinaisons de structure de domaines variables d'anticorps stables |
US11001636B2 (en) | 2016-06-15 | 2021-05-11 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
EP3964526A1 (fr) * | 2008-06-25 | 2022-03-09 | Novartis AG | Humanisation d'anticorps de lapins au moyen d'une région charpente d'anticorps universelle |
AU2020201002B2 (en) * | 2008-06-25 | 2022-04-07 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
US12144865B2 (en) | 2015-06-22 | 2024-11-19 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates with enzymatically cleavable groups |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001088138A1 (fr) * | 2000-05-19 | 2001-11-22 | Scancell Limited | Anticorps humanises contre le recepteur du facteur de croissance epidermique |
-
2007
- 2007-07-06 WO PCT/KR2007/003294 patent/WO2008004834A1/fr active Application Filing
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001088138A1 (fr) * | 2000-05-19 | 2001-11-22 | Scancell Limited | Anticorps humanises contre le recepteur du facteur de croissance epidermique |
Non-Patent Citations (4)
Cited By (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2008246442B2 (en) * | 2007-05-04 | 2014-07-03 | Technophage, Investigacao E Desenvolvimento Em Biotecnologia, Sa | Engineered rabbit antibody variable domains and uses thereof |
US10280211B2 (en) | 2007-05-04 | 2019-05-07 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Engineered rabbit antibody variable domains and uses thereof |
WO2008136694A1 (fr) | 2007-05-04 | 2008-11-13 | Technophage, Investigação E Desenvolvimento Em Biotecnologia, Sa | Domaines variables transgéniques d'anticorps de lapin et leurs utilisations |
EP2307457B1 (fr) | 2008-06-25 | 2018-06-13 | ESBATech, an Alcon Biomedical Research Unit LLC | Anticorps stables et solubles inhibant le tnf |
AU2020201002B2 (en) * | 2008-06-25 | 2022-04-07 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
US11858981B2 (en) | 2008-06-25 | 2024-01-02 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
US11578123B2 (en) | 2008-06-25 | 2023-02-14 | Novartis Ag | Stable and soluble antibodies inhibiting TNFα |
EP2307457B2 (fr) † | 2008-06-25 | 2022-06-22 | Novartis AG | Anticorps stables et solubles inhibant le tnf |
US8293235B2 (en) | 2008-06-25 | 2012-10-23 | ESBATech, an Alcon Biomedical Research Unit, LLC | Humanization of rabbit antibodies using a universal antibody framework |
EP3964526A1 (fr) * | 2008-06-25 | 2022-03-09 | Novartis AG | Humanisation d'anticorps de lapins au moyen d'une région charpente d'anticorps universelle |
US8673310B2 (en) | 2008-06-25 | 2014-03-18 | ESBA Tech, an Alcon Biomedical Research Unit LLC | Stable and soluble antibodies inhibiting TNFα |
AU2009264567B2 (en) * | 2008-06-25 | 2014-06-12 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
JP2011525360A (ja) * | 2008-06-25 | 2011-09-22 | エスバテック、アン アルコン バイオメディカル リサーチ ユニット、エルエルシー | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
EP2752428A1 (fr) * | 2008-06-25 | 2014-07-09 | ESBATech, an Alcon Biomedical Research Unit LLC | Humanisation d'anticorps de lapins au moyen d'une région charpente d'anticorps universelle |
AU2018200640B2 (en) * | 2008-06-25 | 2019-11-21 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
US8937162B2 (en) | 2008-06-25 | 2015-01-20 | ESBATech, an Alcon Biomedical Research Unit, LLC | Humanization of rabbit antibodies using a universal antibody framework |
JP2015120746A (ja) * | 2008-06-25 | 2015-07-02 | エスバテック − ア ノバルティスカンパニー エルエルシー | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
AU2014203813B2 (en) * | 2008-06-25 | 2015-12-03 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
JP2016135815A (ja) * | 2008-06-25 | 2016-07-28 | エスバテック − ア ノバルティス カンパニー エルエルシー | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
US9422366B2 (en) | 2008-06-25 | 2016-08-23 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNF alpha |
AU2013203004B2 (en) * | 2008-06-25 | 2016-09-08 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
WO2009155726A2 (fr) * | 2008-06-25 | 2009-12-30 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanisation d'anticorps de lapins au moyen d'une infrastructure d'anticorps universelle |
US9593161B2 (en) | 2008-06-25 | 2017-03-14 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
US10100111B2 (en) | 2008-06-25 | 2018-10-16 | Esbatech, An Alcon Biomedical Research Unit Llc | Stable and soluble antibodies inhibiting TNF alpha |
US10087244B2 (en) | 2008-06-25 | 2018-10-02 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanization of rabbit antibodies using a universal antibody framework |
AU2016201023B2 (en) * | 2008-06-25 | 2017-10-26 | Novartis Ag | Humanization of rabbit antibodies using a universal antibody framework |
JP2017190352A (ja) * | 2008-06-25 | 2017-10-19 | エスバテック − ア ノバルティス カンパニー エルエルシー | 汎用性抗体フレームワークを用いたイエウサギ抗体のヒト化 |
WO2009155726A3 (fr) * | 2008-06-25 | 2010-07-15 | Esbatech, An Alcon Biomedical Research Unit Llc | Humanisation d'anticorps de lapins au moyen d'une infrastructure d'anticorps universelle |
JP2017192384A (ja) * | 2009-02-24 | 2017-10-26 | エスバテック − ア ノバルティス カンパニー エルエルシー | 細胞表面抗原のイムノバインダーを同定するための方法 |
US9598487B2 (en) | 2010-10-22 | 2017-03-21 | ESBATech, an Alcon Biomedical Unit LLC | Stable and soluble antibodies |
US10570198B2 (en) | 2010-10-22 | 2020-02-25 | Novartis Ag | Stable and soluble antibodies |
US8545849B2 (en) | 2010-10-22 | 2013-10-01 | ESBATech, an Aclon Biomedical Research Unit LLC | Stable and soluble antibodies |
WO2012143495A2 (fr) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Nouveaux conjugués liant-principe actif (adc) et leur utilisation |
WO2012143496A2 (fr) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Nouveaux conjugués liant-principe actif (adc) et leur utilisation |
WO2012143499A2 (fr) | 2011-04-21 | 2012-10-26 | Bayer Intellectual Property Gmbh | Nouveaux conjugués liant-principe actif (adc) et leur utilisation |
WO2013056851A2 (fr) | 2011-10-20 | 2013-04-25 | Esbatech - A Novartis Company Llc | Anticorps stable se liant à de multiples antigènes |
EP3431495A1 (fr) | 2011-10-20 | 2019-01-23 | ESBATech - a Novartis Company LLC | Anticorps stable de liaison aux antigènes multiples |
WO2014206561A1 (fr) | 2013-06-26 | 2014-12-31 | Numab Ag | Structures d'anticorps |
US10022453B2 (en) | 2013-12-23 | 2018-07-17 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCs) with kinesin spindel protein (KSP) |
US11123439B2 (en) | 2015-06-22 | 2021-09-21 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCS) and antibody prodrug conjugates (APDCS) with enzymatically cleavable groups |
EP4406606A2 (fr) | 2015-06-22 | 2024-07-31 | Bayer Pharma Aktiengesellschaft | Conjugués liant-médicament (adc) et conjugués promédicament liant-prinateur (apdcs) avec g clivable par voie enzymatique |
US12144865B2 (en) | 2015-06-22 | 2024-11-19 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates with enzymatically cleavable groups |
WO2016207089A1 (fr) | 2015-06-22 | 2016-12-29 | Bayer Pharma Aktiengesellschaft | Conjugués anticorps-médicament (adc) et conjugués lieur-promédicament (apdc) à groupes enzymatiquement clivables |
WO2017060322A2 (fr) | 2015-10-10 | 2017-04-13 | Bayer Pharma Aktiengesellschaft | Conjugué anticorps-médicament (adc) inhibiteur de ptefb |
WO2017162663A1 (fr) | 2016-03-24 | 2017-09-28 | Bayer Pharma Aktiengesellschaft | Promédicaments de principes actifs cytotoxiques contenant des groupes fissibles par voie enzymatique |
US11685714B2 (en) | 2016-03-24 | 2023-06-27 | Bayer Pharma Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
US11643469B2 (en) | 2016-06-15 | 2023-05-09 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
US11001636B2 (en) | 2016-06-15 | 2021-05-11 | Bayer Pharma Aktiengesellschaft | Specific antibody-drug-conjugates (ADCs) with KSP inhibitors and anti-CD123-antibodies |
US11478554B2 (en) | 2016-12-21 | 2022-10-25 | Bayer Pharma Aktiengesellschaft | Antibody drug conjugates (ADCS) having enzymatically cleavable groups |
US11433140B2 (en) | 2016-12-21 | 2022-09-06 | Bayer Pharma Aktiengesellschaft | Specific antibody drug conjugates (ADCs) having KSP inhibitors |
US11660351B2 (en) | 2016-12-21 | 2023-05-30 | Bayer Aktiengesellschaft | Antibody drug conjugates (ADCs) having enzymatically cleavable groups |
WO2018114578A1 (fr) | 2016-12-21 | 2018-06-28 | Bayer Pharma Aktiengesellschaft | Conjugués liant-principe actif (adc) ayant des groupes enzymatiquement clivables |
WO2018114798A1 (fr) | 2016-12-21 | 2018-06-28 | Bayer Aktiengesellschaft | Promédicaments de principes actifs cytotoxiques contenant des groupes divisibles par voie enzymatique |
US12059472B2 (en) | 2016-12-21 | 2024-08-13 | Bayer Aktiengesellschaft | Prodrugs of cytotoxic active agents having enzymatically cleavable groups |
WO2019057787A1 (fr) | 2017-09-20 | 2019-03-28 | Numab Innovation Ag | Nouvelles combinaisons stables de charpentes de domaines variables d'anticorps |
EP3459968A1 (fr) | 2017-09-20 | 2019-03-27 | Numab Innovation AG | Nouvelles combinaisons de structure de domaines variables d'anticorps stables |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
WO2008004834A1 (fr) | Anticorps monoclonal humanisé à forte liaison au récepteur de facteur de croissance épidermique, récepteur egf | |
US20200255516A1 (en) | Tigit antibody, antigen-binding fragment thereof, and medical use thereof | |
CN102369214B (zh) | 三价、双特异性抗体 | |
WO2017197667A1 (fr) | Anticorps monoclonal humanisé anti-pd-l1 humaine et son utilisation | |
US8748175B2 (en) | Antibodies specifically binding to the epidermal growth factor receptor | |
CN112830969B (zh) | 一种特异性结合人Claudin18.2的单克隆抗体及包含其的药物和试剂盒 | |
EP2727942A1 (fr) | Anticorps bispécifiques contre le EGFR, HER2 et HER3 humains | |
CN115109156B (zh) | 一种靶向bcma的纳米抗体及其应用 | |
CN115605513A (zh) | 一种抗pd-l1和her2的双特异性抗体 | |
IL302490A (en) | A bispecific antibody against A-SYN/IGF1R and its use | |
CN114685666B (zh) | 抗间皮素纳米抗体及其应用 | |
WO2019080909A1 (fr) | Anticorps thérapeutique ciblant rankl | |
EP4269442A1 (fr) | Molécule de liaison à la mésothéline et son utilisation | |
CN114685667B (zh) | 间皮素结合分子及其应用 | |
US20230071019A1 (en) | Compositions and methods for reducing off-target toxicity of antibody drug conjugates | |
EP3239177B1 (fr) | Nouvel anticorps anti-egfrviii et composition le comprenant | |
KR20240099351A (ko) | Gprc5d에 결합하는 항체 및 그 용도 | |
CN116284408A (zh) | 结合人muc17的抗体、其制备方法及用途 | |
CN118240082A (zh) | Pd-1结合分子及其应用 | |
US20240262915A1 (en) | Anti-tigit antibody and double antibody and their application | |
US20230257469A1 (en) | TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE, FUSION PROTEIN OF TGFßR2 EXTRACELLULAR DOMAIN TRUNCATED MOLECULE AND ANTI-EGFR ANTIBODY, AND ANTI-TUMOR USE OF FUSION PROTEIN | |
US11970533B2 (en) | Bispecific antibodies targeting human claudin 18.2 and programmed death-ligand 1 (PD-L1) | |
WO2023109888A1 (fr) | Anticorps bispécifique anti-ang2-vegf et son utilisation | |
CN118834297A (zh) | 泌乳素受体抗体及其用途 | |
CN116284427A (zh) | 抗muc17/cd3双特异性抗体、其制备方法及用途 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 07768638 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
NENP | Non-entry into the national phase |
Ref country code: RU |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 07768638 Country of ref document: EP Kind code of ref document: A1 |